Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH CML 2022 | Design & aims of the EURO-SKI trial in CML

Francois-Xavier Mahon • 22 Oct 2022
ESH CML 2022
Chronic Myeloid Leukemia Leukemia
EURO-SKI

Francois-Xavier Mahon, MD, PhD, University of Bordeaux, Bordeaux, France, briefly outlines the design and objectives of the EURO-SKI (NCT01596114) trial which aimed to better define the prognostic factors for treatment-free remission (TFR) in chronic myeloid leukemia (CML). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Francois-Xavier Mahon

2:18
Recommendations for treatment discontinuation in CML
Francois-Xavier Mahon • 22 Oct 2022
1:24
Key challenges in CML: QoL, managing CML in resource-challenged countries & achieving a cure
Francois-Xavier Mahon • 22 Oct 2022
1:05
Feasibility of treatment cessation in patients with CML with atypical BCR-ABL fusion transcripts
Francois-Xavier Mahon • 26 Nov 2021
4:57
EURO-SKI: 3-year follow-up data of TKI cessation in CML
Francois-Xavier Mahon • 26 Nov 2021

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals